MetaVia Inc. — Director's Dealing 2016

Nov 29, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2016-11-25

Reporting Person: Sooch Mina (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-11-25	Employee Stock Option (right to buy)	$10	A	120000	Acquired	2026-08-03	Common Stock (120000)	Direct

Footnotes

F1: The reporting person was granted an option to purchase 600,000 shares of common stock effective August 4, 2016. 360,000 of the shares underlying the option award were immediately earned on the date of the grant, 120,000 shares underlying the option award were earned on September 30, 2016 following the initiation of the Company's first clinical trial and 120,000 shares underlying the option award are earned upon the initiation of the Company's second clinical trial. The Company has initiated its second clinical trial, so the 120,000 shares underlying the option award that were subject to the initiation of the Company's second clinical trial have been earned.

F2: The option vests in 48 equal consecutive monthly increments, so that all of the shares will be vested on the fourth anniversary of the date of grant.